Objective-Our goal was to test whether formin homology protein 1 (FHOD1) plays a significant role in the regulation of smooth muscle cell (SMC) differentiation and, if so, whether Rho kinase (ROCK)-dependent phosphorylation in the diaphanous autoinhibitory domain is an important signaling mechanism that controls FHOD1 activity in SMC. Methods and Results-FHOD1 is highly expressed in aortic SMCs and in tissues with a significant SMC component.
S mooth muscle cell (SMC) differentiation is an important component of vascular development, and defective control of this process in adult animals has been shown to contribute to a variety of cardiovascular pathologies, including atherosclerosis and restenosis (see 1 for review). It is well known that SMC differentiation marker gene expression is regulated by serum response factor binding to conserved CArG cis elements within the SMC-specific promoters. The myocardin family of serum response factor cofactors (myocardin and the myocardin-related transcription factor-[MRTF]-A/ megakaryoblastic leukemia-1 and MRTF-B/megakaryoblastic leukemia-2) are also critical and have been shown to be required for SMC differentiation marker gene expression in a variety of in vitro and in vivo models. [2] [3] [4] [5] Thus, identifying the signaling mechanisms by which extrinsic cues regulate serum response factor/myocardin factor activity will be critical for our understanding of the control of SMC phenotype.
Miralles et al were the first to demonstrate that MRTF-A activity is controlled by the small GTPase RhoA and that MRTF-A nuclear localization was enhanced by RhoAdependent actin polymerization. 6 Studies from our laboratory and others have shown that regulation of MRTF-A and MRTF-B by this mechanism plays an important role in the regulation of SMC phenotype in at least some SMC subtypes. [7] [8] [9] Of the RhoA effector proteins, Rho kinase (ROCK)
is the most well studied and has been shown to enhance actin polymerization through LIM kinase-mediated inhibition of cofilin and to stimulate contractility by inhibiting myosin phosphatase. Although the ROCK inhibitor Y-27632 attenuates SMC-specific transcription, 10, 11 it is clear that other RhoA effectors are also involved.
Actin polymerization is also regulated by formin proteins that directly catalyze actin polymerization through 2 highly conserved formin homology domains (FH1 and FH2) that bind profilin and actin, respectively (see 12, 13 for reviews). Members of the diaphanous-related formin (DRF) subfamily (mDia1, mDia2, mDia3, and formin homology protein 1 [FHOD1]) exist in an autoinhibited state maintained by a molecular interaction between the N-terminal diaphanous inhibitory domain (DID) and the C-terminal diaphanous autoregulatory domain (DAD) (see Figure 1A ). Importantly, the DRFs interact with specific Rho GTPases (Rho, Rac, Cdc42) through a conserved GTPasebinding domain positioned near the DID. Studies of mDia1 autoinhibition have demonstrated that RhoA binding to the GTPase-binding domain interferes with the DID-DAD interaction, thus promoting mDia1-mediated actin nucleation. 14, 15 mDia2 is also activated by RhoA, and we have recently shown that both of these DRFs are highly expressed in SMC and are critical for RhoA's effects on SMC-specific gene expression and MRTF nuclear localization. 16 FHOD1 has not been as extensively studied, but on the basis of several early observations, we assumed that it was not a major regulator of SMC differentiation marker gene expression. First, FHOD1 binds only to Rac, which, unlike RhoA, has only minimal effects on SMC-specific gene expression. 10 Second, Rac binding does not activate FHOD1 but serves as a mechanism for localizing FHOD1 to the plasma membrane. 17 Finally, although FHOD1 was shown to be expressed in human SMC and endothelial cell lines, 18, 19 it was unclear whether FHOD1 was expressed at appreciable levels in SMC in vivo. Importantly, Takeya et al recently demonstrated that FHOD1 was phosphorylated by ROCK at multiple S/T residues in the DAD domain in endothelial cells and that this phosphorylation interfered with the DID-DAD interaction. 19 These studies were of considerable interest because they were the first to identify an activation mechanism for FHOD1, and more importantly, they implicated FHOD1 as an actin nucleating protein downstream of RhoA. Thus, we wanted to test whether FHOD1 played a significant role in the regulation of SMC differentiation and, if so, whether ROCK-dependent phosphorylation was an important signaling mechanism that controlled FHOD1 activity in SMC.
Materials and Methods

Plasmids and Reagents
cDNA encoding human FHOD1 and MRTF-A/B plasmids were a kind gift from Michael Mendelsohn (Tuffs Medical Center, Boston, Mass) and Da-Zhi Wang (Children's Hospital, Harvard Medical School, Boston, Mass), respectively. pCMV-Myc-ROCK⌬3 was a generous gift from Keith Burridge (University of North, Chapel Hill, NC). Full-length and truncation mutations of FHOD1 were generated by polymerase chain reaction and subcloned into the expression plasmid pcDNA3.1 (Clontech). Aspartate substitutions at Ser1131, Ser1137, and Thr1141 were generated using the Quikchange Site-Directed Mutagenesis Kit (Stratagene). The anti-MRTF-A antibody was generated by us and has been previously described. 9 The SM22␣ antibody was a kind gift from Mario Gimona (University of Salzburg, Salzburg, Austria), All other antibodies were purchased commercially: FHOD1 and FHOD1 pThr1141 (ECM Biosciences), M2-flag and smooth muscle (SM) ␣-actin (Sigma), GAPDH (Santa Cruz), SM-MHC (Abbiotec), ␤-actin, extracellular signal regulated kinase (ERK), and phospho-ERK (Cell Signaling). Y-27632 and latrunculin B were purchased from Calbiochem, and sphingosine-1phosphate (S1P) was from Cayman Chemicals.
Cell Culture, Transient Transfections, and Reporter Gene Assays
SMCs from mouse thoracic aorta were isolated and cultured as previously described. 7 The maintenance and transfection of multi- Figure 1 . FHOD1 was expressed in SMC-containing tissues and stimulated SMC-specific gene transcription. A, Molecular regulation of FHOD1. ROCKdependent phosphorylation of 3 conserved residues within the DAD domain activates FHOD1, whereas binding to Rac regulates FHOD1 subcellular localization. B, Western blot of FHOD1, SM ␣-actin, SM22, and GAPDH expression in the indicated cell lines and tissues from adult C57/Bl6 mice. C, flag-tagged WT or ⌬GTPase-binding domain (⌬GBD)/DID FHOD1 variants were transfected into 10T1/2 cells along with luciferase reporter constructs driven by the indicated promoter. Luciferase activity was analyzed at 24 hours and is expressed relative to plus empty vector (EV). The inset shows protein expression. *PϽ0.05 versus plus empty vector. potential 10T1/2 cells were performed as previously described. 16 In brief, cells were maintained in 48-well plates in 10% serum and were transfected 24 hours after plating at 70% to 80% confluence using the transfection reagent, TransIT-LT1 (Mirus), as per protocol. Luciferase assays (Promega) were conducted 24 hours following transfection. The SM22, SM ␣-actin, and c-fos promoters have been described previously. 10, 20 Short Interfering RNA Knockdown FHOD1 was depleted from primary mouse aortic SMCs using short interfering RNA (siRNA) (Dharmacon) with the following sequences: sense, 5Ј-GGAAGAGCGGCAGAAGAUUGAGGTT; antisense, 5Ј-CCUCAAUCUUCUGCCGCUCUUCCTT. Cells were transfected with gene-specific siRNA (100 nmol/L) or nontargeted control (NTC) siRNA designed against green fluorescent protein using DharmaFECT reagent 1. After 72 hours of knockdown, cells were serum starved for 24 hours and left untreated or treated with S1P (10 mol/L) for an additional 24 hours or 12.5 minutes (Erk phosphorylation).
Western Blots
Samples were lysed in buffer A (50 mmol/L Tris [pH 7.2], 150 mmol/L NaCl, 2 mmol/L EDTA, 1% NP-40, 0.5% Triton X-100) and cleared by centrifugation (4°C for 15 minutes at 14 000 rpm). Protein concentrations were determined by BCA assay (Pierce). Protein lysates were run on SDS polyacrylamide gels, transferred to nitrocellulose, and probed with the indicated antibodies.
Immunofluorescence 10T1/2 cells were plated and transfected in 4-well chamber slides and maintained overnight in media containing 10% serum. Cells were serum starved for 16 hours, fixed in 3.7% paraformaldehyde/ phosphate-buffered saline for 20 minutes, and permeabilized in 0.5% Triton X-100/phosphate-buffered saline for 3 to 4 minutes. The M2 flag (1:500), SM ␣-actin (1:2000), or MRTF-A (1:250) Abs were diluted in 20% goat serum/3% bovine serum albumin in phosphatebuffered saline and incubated with the fixed cells for 2 hours. Texas Red-or fluorescein isothiocyanate (Jackson ImmunoResearch)conjugated secondary antibodies were used at 1:1000, whereas Alexa Fluor 555 phalloidin (Molecular Probes) and 4Ј,6-diamidino-2phenylindole (Molecular Probes) were used at 1:100 and 1 nmol/L, respectively.
Actin Sedimentation Assays
SMCs transfected with control or FHOD1 siRNA (see above) were subject to actin sedimentation assays as previously described. 21 In brief, cell lysates were centrifuged at 100 000g for 1 hour and the supernatant (G-actin fraction) and pellet (F-actin fraction) were subjected to Western blot analysis for ␤-actin. In some experiments, cells were treated with Y-27632 (Y) for 8 hours before luciferase determination. *PϽ0.05 versus without FHOD1, **PϽ0.05 versus L63 RhoAϩFHOD1. B, Primary mouse SMCs were serum starved for 24 hours and then pretreated with increasing amounts of Y-27632 (10, 25, 50, or 100 mol/L) for 90 minutes and the phosphatase inhibitor calyculin A (50 nmol/L) for 5 minutes. After addition of S1P (10 mol/L), FHOD1 phosphorylation was measured at 7.5 minutes using a phosphospecific antibody against Thr-1141. C and E, 10T1/2 cells were transfected with WT FHOD1 or an FHOD1 variant containing phosphomimetic mutations to the 3 ROCK target residues within the autoinhibitory domain (3xD). Cells were serum starved in media containing 0.5% FBS for 24 hours and then stained for actin polymerization (C) or endogenous SM ␣-actin expression (E). DAPI indicates 4Ј,6-diamidino-2-phenylindole. D, The indicated flag-FHOD1 variants and luciferase reporters were transfected into 10T1/2 cells, and luciferase activity was measured at 24 hours. *PϽ0.05 versus WT, **PϽ0.05 versus 3xD.
Results
FHOD1 Is Expressed in SMC-Containing Tissues and Stimulates SMC-Specific Gene Transcription
To begin to address whether FHOD1 was an important regulator of SMC phenotype, we measured FHOD1 expression in mouse tissues and several cell lines by Western blot ( Figure 1B) . Although FHOD1 was detected in many tissues, in general, its expression was relatively high in many tissues that exhibited strong SMC differentiation marker gene expression, including bladder, lung, stomach, and primary aortic SMCs. To determine whether FHOD1, like mDia1 and mDia2, could stimulate SMC-specific transcription, we expressed flag-tagged FHOD1 variants in multipotential 10T1/2 cells along with several SMC-specific promoter-luciferase constructs. 10T1/2 cells serve as an excellent model for studying the signaling pathways that regulate SMC phenotype because we and others have shown that SMC differentiation marker gene expression can be dramatically upregulated by exogenously expressed proteins or by treatment with various agonists, such as transforming growth factor-␤ and S1P. 7, 22 Figure 1C demonstrates that expression of wild-type (WT) FHOD1 had no effect on any of the promoters tested reflecting the autoinhibited nature of the full-length molecule. However, expression of a constitutively active FHOD1 variant that lacks the N-terminal autoinhibitory domain (⌬GTPase-binding domain/DID) strongly stimulated SMCspecific promoter activity (by 8-to 25-fold) even though it was expressed at a slightly lower level than the WT variant. Importantly, constitutively active FHOD1 had no effect on the CArG-containing c-fos promoter or on the CArGindependent minimal thymidine kinase promoter suggesting that this effect was at least somewhat specific.
FHOD1 Activity in SMC Is Regulated by ROCK
Although constitutively active FHOD1 was sufficient to activate SMC-specific transcription, we were interested in whether FHOD1 activity in our SMC differentiation models was controlled by ROCK-dependent phosphorylation. To test this, we measured SM22 promoter activity in 10T1/2 cells coexpressing FHOD1 and constitutively active variants of RhoA (L63) or ROCK (⌬3). As shown in Figure 2A , expression of L63RhoA or ROCK⌬3 by itself enhanced SM22 promoter activity Ϸ6-fold and 4-fold, respectively, whereas expression of FHOD1 had little effect. However, coexpression of FHOD1 with L63RhoA resulted in a synergistic activation of SM22 promoter activity (to approximately 15-fold), suggesting that these signaling molecules cooperate to regulate SMC-specific expression. Importantly, this increase was significantly attenuated by the ROCK inhibitor, Y-27632, and a similar synergy was observed on coexpression of ROCK⌬3 with FHOD1. In contrast, coexpression of FHOD1 with constitutively active Rac (L61) did not lead to synergistic activation of SMC differentiation marker gene expression, but it did result in FHOD1 localization to the plasma membrane and a relatively small increase in cortical actin polymerization (Supplemental Figure I , available online at http://atvb.ahajournals.org).
It has been shown in endothelial cells that FHOD1 was phosphorylated by ROCK at 3 highly conserved sites (Ser1131, Ser1137, and Thr1141) just C-terminal to the core DAD domain and that phosphorylation of these residues activated FHOD1 by interfering with the DID-DAD interaction. 19 To test whether endogenous FHOD1 was phosphorylated by ROCK in SMC we used a phosphospecific antibody against Thr1141. As shown in Figure 2B , treatment of cells with S1P, a lipid agonist previously shown to activate RhoA in SMC, 7 resulted in a significant increase in Thr1141 phosphorylation. Importantly, S1P-dependent Thr1141 phosphorylation and basal Thr1141 phosphorylation were inhibited by Y-27632, strongly indicating that ROCK phosphorylates FHOD1 in SMC. To directly test whether phos- phorylation activates FHOD1 in SMC, we generated an FHOD1 variant that contained phosphomimetic aspartic acid mutations to all 3 residues shown to be phosphorylated by ROCK (3xD). In comparison with WT, the 3xD variant significantly enhanced FHOD1 activity as measured by actin polymerization (Figure 2C ), SMC-specific promoter activity ( Figure 2D) , and endogenous SM ␣-actin expression ( Figure  2E) . Interestingly, the 3xD variant was not quite as active as the constitutively active FHOD1 variant lacking the entire DAD domain (⌬DAD).
FHOD1 Activity Regulates MRTF Nuclear Localization
On the basis of our previous studies on mDia1 and mDia2, we hypothesized that the effect of FHOD1 on SMC-specific transcription was mediated by an actin polymerizationdependent enhancement of MRTF nuclear localization. In support of this idea, the ability of the FHOD1 3xD variant to stimulate SM22 promoter activity was strongly inhibited by the actin polymerization inhibitor latrunculin B ( Figure 3A) or by coexpression with a dominant-negative MRTF ( Figure  3B ). Furthermore, the 3xD variant synergistically enhanced transactivation of the SM22 promoter by MRTF-B, an effect not observed with WT FHOD1 (Figure 3C ). In excellent agreement with these findings, endogenous MRTF-A ( Figure   3D ) and green fluorescent protein-MRTF-B ( Figure 3E ) localized to the nucleus in 100% of cells expressing the phosphomimetic FHOD1 variant, whereas cells expressing WT FHOD1 exhibited little MRTF nuclear localization (16Ϯ5% for MRTF-A, PϽ0.05; and 3Ϯ2% for green fluorescent protein-MRTF-B, PϽ0.05).
FHOD1 Is Required for S1P-Dependent SMC Differentiation
Because we have previously shown that S1P upregulates SMC differentiation marker gene expression through a RhoA-dependent increase in actin polymerization, 7 we wanted to determine whether endogenous FHOD1 was required for this response. We used standard siRNA methods to knock down FHOD1 expression in SMCs, and as shown in Figure 4B , we consistently achieved about a 60% to 70% reduction in FHOD1 protein when compared with cells transfected with NTC siRNA. Treatment of serum-starved SMC with S1P resulted in a significant increase in endogenous SM MHC, SM22, and SM ␣-actin expression in control cells, and importantly, this increase was significantly attenuated in the FHOD1 knockdown SMC ( Figure 4A ). Knockdown of FHOD1 had no effect on GAPDH expression, tubulin expression (data not shown), or S1P-dependent activation of ERK ( Figure 4C) , indicating that depletion of . Knockdown of FHOD1 in SMC inhibited SMC differentiation marker gene expression. A, Primary aortic SMC were transfected with NTC or FHOD1 siRNAs for 72 hours. Following 24 hours of complete serum starvation, cells were treated with S1P for an additional 24 hours. Lysates were subjected to Western blot analysis using the indicated antibody. B, Quantification of FHOD1 and SM marker gene expression from 5 independent experiments. Protein expression was normalized to GAPDH expression and is expressed relative to NTC cells treated with S1P set to 1. *PϽ0.05. C, Control and FHOD1 knockdown SMC were treated with S1P for 12.5 minutes. ERK activity was then measured by Western blotting using a phosphospecific ERK antibody. FHOD1 did not have significant negative effects on normal cell function or other S1P-dependent signaling pathways.
We also measured changes in actin polymerization in this model. As shown in Figure 5 , treatment of control SMCs with S1P increased stress fiber formation as measured by phalloidin staining and significantly increased the ratio of F-actin to G-actin as measured by actin sedimentation assays. Importantly, knockdown of FHOD1 significantly attenuated these S1P-induced changes. These results are in excellent agreement with the downregulation of SMC differentiation marker gene expression observed in FHOD1 depleted SMC and strongly suggest that FHOD1 plays a critical role in the RhoA-dependent regulation of SMC phenotype.
Discussion
Extensive evidence indicates that RhoA activity stimulates SMC differentiation marker gene expression by promoting MRTF activity (reviewed by Parmacek 23 ). This effect is mediated by increased actin polymerization, and we have previously demonstrated that the RhoA effectors mDia1 and mDia2 are involved in this response. We now demonstrate that an additional member of the mDia family, FHOD1, is also highly expressed in SMC and regulates RhoA-dependent stimulation of actin polymerization and SMC differentiation marker gene expression. Interestingly, FHOD1 activity in SMC is not directly regulated by an interaction with RhoA. Instead, our data indicate that FHOD1 is regulated by ROCK-dependent phosphorylation.
It is clear that disruption of the autoinhibitory DID-DAD interaction is required for DRF activation. Crystal structure studies have revealed that the highly conserved amphipathic core DAD sequence MDSLLEAL binds tightly to a hydrophobic pocket on the DID surface. 15 In addition, a highly conserved basic domain just C-terminal to the core DAD contributes to the DID-DAD interaction, strongly suggesting that electrostatic forces are also important. 24 Although GTPase binding is critical for the activation of most DRFs, it is becoming clear that other mechanisms are also involved (see review 12 ). Our results indicate that FHOD1 is phosphorylated by ROCK in SMC and provide further support for the idea that phosphorylation disrupts the DID-DAD interaction to activate FHOD1. 19 Interestingly, the 3xD phosphomimetic did not stimulate SMC-specific transcription as strongly as the constitutively active ⌬DAD variant, perhaps suggesting that other factors are required for full FHOD1 activation in SMC. Providing additional support for this alternative activation mechanism, we have recently demonstrated that mDia2 activity is also enhanced by ROCK-dependent phosphorylation of 2 conserved S/T residues just C-terminal to the DAD basic domain (D.P. Staus and C.P. Mack, unpublished data, 2010) . Whether mDia1 or mDia3 are regulated by phosphorylation has not been examined, but this mechanism could provide specificity to DRF activation and additional spatial and/or temporal control over FHOD1 and mDia2 activity.
Because RhoA activates a number of downstream effectors that regulate actin polymerization and cytoskeletal remodeling, it has been somewhat difficult to determine the precise contributions of each to the control of SMC differentiation marker gene expression. The negative effects of Y-27632 on SMC differentiation marker gene expression have been attributed mainly to attenuation of LIM kinase/cofilin signaling. 7, [25] [26] [27] However, in light of the current results, decreased FHOD1 and mDia2 activity must also be taken into account. Our demonstration of relatively high FHOD1 expression in SMC when coupled with the results of our gain/loss of function experiments indicate that FHOD1 plays a significant role in regulating SMC phenotype. Interestingly, individual knockdowns of mDia1 or mDia2 also decreased SMCspecific gene expression in this model (data not shown) suggesting that each of these DRFs has a nonredundant function required for full MRTF activation, or alternatively, that these proteins interact functionally or physically to regulate actin polymerization. In support of the latter, we have recently demonstrated that endogenous mDia2 and FHOD1 could be coimmunoprecipitated from SMC lysates (D.P. Staus and C.P. Mack, unpublished data). Interestingly, we have not yet observed statistically significant changes in endogenous MRTF-A nuclear localization in FHOD1 knockdown SMC on S1P-treatment (at least at early time points), and it is possible that FHOD1 knockdown inhibits SMCspecific gene expression by other mechanisms downstream of MRTF nuclear localization, perhaps at the level of transcription complex formation. Clearly, additional experiments will be required to determine the precise importance of each of the RhoA-dependent DRFs and whether they have specific functions in regulating SMC differentiation.
Activation of FHOD1 by DAD phosphorylation may present a unique mechanism by which different signaling pathways can converge to regulate SMC phenotype. For example, cGMP-dependent protein kinase has been shown to promote the contractile SMC phenotype in vitro and in vivo, but the mechanism by which this occurs is not well understood. 28, 29 Interestingly, cGMP-dependent protein kinase has also been shown to phosphorylate the FHOD1 DAD at Ser-1131, 18 and it is intriguing to postulate that phosphorylation-dependent activation of FHOD1 may explain the effects of cGMPdependent protein kinase on SMC marker gene expression.
In summary, our results indicate that FHOD1 plays a critical role in RhoA-dependent regulation of SMC-specific gene expression and that ROCK-dependent phosphorylation regulates FHOD1 activity in SMC ( Figure 6 ). The importance of FHOD1 in SMC differentiation during vascular development and its importance in the progression of cardiovascular disease will be critical areas for future investigation.
Sources of Funding
This work was supported by National Institutes of Health Grants HL-070953 (to C.P.M.) and HL-102446 (to J.M.T.) and American Heart Association Grant 07152340U (to D.P.S.). Figure 6 . The RhoA-dependent signaling pathways that regulate SMC differentiation. RhoA activates mDia1, mDia2, and ROCK through direct binding. ROCK activity stimulates actin polymerization through LIM kinase (LIMK)-mediated inhibition of cofilin. Our recent results (shaded box) suggest that ROCK also enhances the activities of FHOD1 and mDia2 through direct phosphorylation of the DAD autoregulatory domains of these proteins. Collectively, these pathways reduce cellular G-actin pools leading to MRTF nuclear accumulation, and our data suggest that all 3 DRFs are required for full RhoA-dependent activation of SMC-specific gene expression.
